tradingkey.logo
搜索

Eton Pharmaceuticals Inc

ETON
添加自选
37.500USD
+0.870+2.38%
收盘 07/02, 13:00美东报价延迟15分钟
1.03B总市值
亏损市盈率 TTM

关于 Eton Pharmaceuticals Inc 公司

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc简介

公司代码ETON
公司名称Eton Pharmaceuticals Inc
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)
员工数量31
证券类型Ordinary Share
年结日Nov 09
公司地址21925 W Field Pkwy Ste 235
城市DEER PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编60010-7278
电话18477877361
网址https://etonpharma.com/
公司代码ETON
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)

Eton Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

常见问题

Eton Pharmaceuticals Inc的前五大股东是谁?

Eton Pharmaceuticals Inc 的前五大股东如下:Mr. Sean E. Brynjelsen

有多少机构持有Eton Pharmaceuticals Inc(ETON)的股份?

截至2026Q1,共有235家机构持有Eton Pharmaceuticals Inc的股份,合计持有的股份价值约为15.99M,占公司总股份的58.43%。与2025Q4相比,机构持股有所增加,增幅为-3678435.00。